This is a single arm, Simon two-stage historically controlled study to compare the 4 month progression-free survival rate of patients with relapsed/refractory osteosarcoma treated with regorafenib in combination with nivolumab to those who received regorafenib alone (historical control).
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.